Christie Fanton
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune Cell Function and Interaction, Cancer Mechanisms and Therapy, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)(2020)232 cited
- → A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors(2019)229 cited
- → The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece.(1993)149 cited
- → Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers(2014)111 cited
- → Induction of Tubulogenesis in Telomerase-Immortalized Human Microvascular Endothelial Cells by Glioblastoma Cells(2002)110 cited
- → Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors(2018)66 cited
- → Dual Growth Arrest Pathways in Astrocytes and Astrocytic Tumors in Response to Raf-1 Activation(2001)58 cited
- → NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases(2021)51 cited
- → Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus(2022)32 cited
- → The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials(2024)26 cited